CDKN2A and cancer: Moreover, CDK4/6 inhibitors, which mimic the function of p16, have been demonstrated to induce senescence in various cancer cells [50–53], reducing the proliferative capacity of activated T cells while preserving their cytotoxic efficacy [54].